Prevalence and Clinical Relevance of Exon 2 Deletion of COMMD1 in Bedlington Terriers in Korea

J Vet Intern Med. 2016 Nov;30(6):1846-1850. doi: 10.1111/jvim.14590. Epub 2016 Oct 11.

Abstract

Background: Deletion of exon 2 of copper metabolism domain containing 1 (COMMD1) results in copper toxicosis in Bedlington terriers (CT-BT).

Objectives: This study was conducted to identify the prevalence and clinical relevance of the COMMD1 mutation in Bedlington terriers in Korea.

Animals: A total of 105 purebred Bedlington terriers (50 males, 55 females) from the kennels and pet dog clubs in Korea were examined during the period 2008-2013.

Methods: A multiplex PCR was carried out to detect exon 2 deletion of COMMD1. Clinical analysis was performed on each genetic group, and clinical status of the dogs was followed up to estimate survival probability.

Results: Of the 105 samples, 52 (49%) were wild-type homozygote, 47 (45%) were heterozygote, and 6 (6%) were mutant-type homozygote. Plasma alanine aminotransferase (ALT) activity was increased in the mutant-type homozygous group >2 years of age (P < .0001). The survival probability of 6 mutant-type homozygotes surviving 2.5 years was 0.67, and 4 years was 0.5.

Conclusions and clinical importance: Results show the prevalence and clinical relevance of exon 2 deletion of COMMD1 and could help establish a structured selective breeding program to prevent CT-BT in Korea.

Keywords: Copper metabolism; Copper toxicosis; Delete mutation; Survival probability.

MeSH terms

  • Alanine Transaminase / blood
  • Animals
  • Carrier Proteins / genetics*
  • Copper / metabolism
  • Copper / toxicity*
  • Dog Diseases / genetics*
  • Dog Diseases / metabolism
  • Dogs
  • Exons
  • Female
  • Male
  • Metabolism, Inborn Errors / genetics
  • Metabolism, Inborn Errors / veterinary*
  • Mutation
  • Prevalence
  • Republic of Korea
  • Survival Analysis

Substances

  • Carrier Proteins
  • Copper
  • Alanine Transaminase